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Rhesus monkey rhadinovirus (RRV) is one of the closest phylogenetic relatives to the human pathogen
Kaposi’s sarcoma-associated herpesvirus (KSHV), yet it has the distinct experimental advantage of entering
efficiently into lytic replication and growing to high titers in culture. RRV therefore holds promise as a
potentially attractive model with which to study gammaherpesvirus structure and assembly. We have isolated
RRV capsids, determined their molecular composition, and identified the genes encoding five of the main
capsid structural proteins. Our data indicate that, as with other herpesviruses, lytic infection with RRV leads
to the synthesis of three distinct intranuclear capsid species. However, in contrast to the inefficiency of KSHV
maturation following reactivation from latently infected B-cell lines (K. Nealon, W. W. Newcomb, T. R. Pray,
C. S. Craik, J. C. Brown, and D. H. Kedes, J. Virol. 75:2866-2878, 2001), de novo infection of immortalized
rhesus fibroblasts with RRV results in the release of high levels of infectious virions with genome-containing
C capsids at their center. Together, our findings argue for the use of RRV as a powerful model with which to
study the structure and assembly of gammaherpesviruses and, specifically, the human rhadinovirus, KSHV.
Herpesvirus infection persists for the life of the host. In an
immunocompromised state, gammaherpesviruses, one of the
three subtypes of herpesviruses, can lead to severe disease,
including neoplasia (3, 7, 9, 20, 36, 37, 48). The most recently
identified human gammaherpesvirus is the rhadinovirus Kapo-
si’s sarcoma-associated herpesvirus (KSHV) (12), the etiologic
agent of Kaposi’s sarcoma, a human vascular tumor especially
frequent in AIDS patients (5, 8, 9, 21, 29, 35). KSHV is also
associated with two lymphoproliferative diseases, primary ef-
fusion lymphoma and multicentric Castleman’s disease (7, 10,
19, 51).
Rhesus monkey rhadinovirus (RRV) is closely related to
KSHV (15). The sequences, as well as gene content and overall
organization, are well conserved between the two viruses. Fur-
thermore, RRV can lead to the development of a multicentric
lymphoproliferative disorder resembling multicentric Castle-
man’s disease in macaques coinfected with simian immunode-
ficiency virus (34, 58). In contrast to KSHV, however, RRV
grows lytically to high titers following de novo infection of
immortalized rhesus fibroblasts (15–17, 34, 58).
For all herpesviruses, including both human and rhesus
rhadinoviruses, virion formation and release are critical to
horizontal spread within the host and transmission within a
population. One of the earliest steps in virion formation is
assembly of the icosahedral capsid in the nucleus of an infected
cell. Release of fully formed virions follows only after such
capsids acquire a single copy of the linear viral genome and
then an outer proteinaceous tegument layer that is subse-
quently surrounded by a lipid envelope. The entire process
takes approximately 9 h for alphaherpesviruses such as herpes
simplex virus type 1 (HSV-1) (6, 14, 27) but up to 3 or more
days for gammaherpesviruses such as KSHV (38). The rela-
tively slow kinetics of virion formation and release is charac-
teristic of gammaherpesviruses, including the only other
known human member, Epstein-Barr virus, belonging to the
Lymphocryptovirus genus (1, 26, 33, 44, 50).
A mature infectious herpesvirus virion contains one copy of
the double-stranded DNA viral genome within its capsid. Each
capsid is an icosahedron with a triangulation number of 16 and
consists of 162 capsomers characteristic of all members of the
Herpesviridae family (25). Of the 162 capsomers, 12 are pen-
tons, while the remaining 150 are hexons, composed of five and
six subunits of the major capsid protein (MCP), respectively
(24, 38, 40, 52). In addition, the capsids have 320 triplex sub-
units, each consisting of a heterotrimer with 12 stoichiome-
try. During lytic replication of herpesviruses, multiple capsid
species arise (22, 24, 25, 38, 52). These include the three major
capsid species: (i) A capsids lacking internal structures, (ii) B
capsids containing an inner scaffolding protein (SCAF), and
(iii) C capsids enclosing the viral genome but lacking SCAF.
Investigation of the structure and assembly of gammaher-
pesvirus capsids not only will allow a better understanding of
specific aspects of the early steps in virion production that may
distinguish this subfamily of herpesviruses but also may pro-
vide potential insights into future drug targets for human-
specific viruses such as KSHV. However, the goal of develop-
ing a more detailed picture of human gammaherpesvirus
capsid and virion structure and assembly has met with consid-
* Corresponding author. Mailing address: Myles H. Thaler Center
for AIDS and Retrovirus Research, University of Virginia Health
System, P.O. Box 800734, Jordan Hall, Rm. 7069, 1300 Jefferson Park
Ave., Charlottesville, VA 22908-0734. Phone: (434) 243-2758. Fax:
(434) 982-1071. E-mail: kedes@virginia.edu.
13439
FIG. 1. Maturation of RRV particles. (A) TEM of intranuclear RRV capsids 6 days postinfection. Three morphologically distinct capsid species
are evident. The inset displays the dashed boxed area at a greater magnification with type A, B, and C capsids indicated. (B) Released RRV
particles collected from the supernatant of infected RhF. Virions contain a capsid with an inner density surrounded by a tegument layer (t) and
an envelope layer with protrusions consistent with glycoproteins (g). A capsid (c) lacking these two outer layers is also present in this micrograph.
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erable difficulty due to the low yields of virus in in vitro culture
systems or the propensity to enter a state of latency after
infection (28, 30, 38, 43). In contrast, RRV displays robust
lytic-phase growth and high viral titers and thus holds great
promise as an attractive model with which to help characterize
the formation of its human rhadinovirus counterpart, KSHV,
as well as gammaherpesviruses in general.
Capsid and viral isolation. Herpesvirus capsids assemble in
the nuclei of infected cells. To determine if lytic replication of
RRV gives rise to different capsid species, we infected telo-
merase-immortalized rhesus macaque fibroblasts (RhF) for 2 h
with crude preparations of RRV as described previously (2, 15,
16) and then monitored lytic replication by both electron mi-
croscopy and biochemical analysis. The goal was to generate
sufficient numbers of capsids to allow their compositional and
structural characterization. We harvested and fixed infected
cells for thin-section transmission electron microscopy (TEM)
and found that by 4 to 6 days after infection, three capsid
species with distinct morphologies arose in the nuclei (Fig.
1A). We reasoned that lysis of infected cells at late stages of
lytic replication of RRV would lead to the release of these
capsids, as well as viral particles at various stages of matura-
tion, mirroring our earlier findings with KSHV (38).
To maximize the yield of viral and subviral particles, we next
determined the kinetics of total particle release, collecting the
medium at 24-h intervals and subjecting it to centrifugation
through a sucrose cushion, followed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) to visualize
particle-associated protein bands. Maximum release of parti-
cles occurred 6 days postinfection (data not shown). On the
basis of these findings, we collected RRV capsids and virions
for all subsequent biochemical and imaging studies 6 days
postinfection.
We first examined the morphology of released RRV parti-
cles to assess the proportion of mature enveloped virions.
After partial purification by size exclusion column chromatog-
raphy, the otherwise untreated population sedimented through
a sucrose gradient as a single dominant band. Fractions from
the gradient that corresponded to the fastest-sedimenting por-
tion of this visible band contained a fairly homogeneous col-
lection of enveloped virions, although capsids or maturing par-
ticles were also occasionally present (Fig. 1B). Of note in three
separate experiments, nearly all (239 of 241) of the enveloped
particles that we purified in this way and then examined by
TEM possessed an inner density suggestive of encapsidated
viral DNA (22, 25, 38, 42). The near absence of enveloped
particles with empty capsids or no capsid at all (L particles), as
can arise during HSV-1 replication (54), suggests that lytic
replication of RRV is highly efficient in producing mature
virions.
We next focused on characterizing the composition and
structure of RRV capsids. Extrapolating from our work on
KSHV, as well as studies of other herpesviruses (18, 38, 39, 42),
we hypothesized that the three capsid species (A, B, and C)
resulting from RRV lytic replication would each have a distinct
density, allowing their separation by sedimentation through
sucrose gradients (38). We used 2% Triton X-100 detergent to
remove tegument and envelope layers from virions and par-
tially wrapped capsids released during the late stages of lytic
replication. This approach converts the complex population of
particles to a more homogeneous collection of capsid species.
It is possible, however, that a subset of tegument proteins,
especially those tightly associated with the capsid surface, may
remain, at least in part, when this protocol is used. Neverthe-
less, a similar approach led to moderately pure preparations of
KSHV capsids (38, 57), arguing for the efficacy of this ap-
proach.
After such treatment, velocity sedimentation through su-
crose gradients gave rise to three distinct, light-diffracting
bands (Fig. 2) that we tentatively labeled as comprising A, B,
and C capsids, respectively, on the basis of earlier studies of
herpesvirus capsid purification (38, 42). We found that the C
capsid band was consistently the most abundant, followed by B
and then A capsid bands (relative intensity of gradient bands in
Fig. 2). It is likely that de-enveloped virions were the major
contributor to this C capsid predominance.
To confirm that the three light-scattering bands in the su-
crose gradient represented intact capsid particles, we collected
fractions by bottom puncture and subjected each to TEM.
Prior to gradient separation, the detergent-treated particles
comprised a mixture of capsid species with cross sections char-
acteristic of A, B, and C herpesvirus capsid morphologies (Fig.
3A). In contrast, after velocity sedimentation, the fractions
corresponding to the visible bands in the gradient demon-
strated relatively homogeneous populations of RRV capsids,
each with a distinct morphology. The capsids in band A ap-
peared empty (Fig. 3B), the capsids in band B possessed an
inner ring-like structure (Fig. 3C), and the capsids in band C
demonstrated a single inner density, sometimes with thin and
irregular spoke-like projections extending to the edges of the
capsid’s interior (Fig. 3D). These morphologies are consistent
with the A, B, and C capsids comprising the three bands,
respectively, in similarly purified capsids from other herpesvi-
ruses, including KSHV and HSV-1 (22, 38).
Protein characterization of RRV capsids. To determine the
protein composition of the three capsid species, we next ana-
lyzed each fraction of the capsid gradient by SDS-PAGE (Fig.
4) and found protein banding patterns similar to those of
KSHV (38) and other herpesviruses (22, 55). The peak inten-
sities of these particle-associated proteins coincided with the
fractions containing the A, B, and C capsid particles (Fig. 3),
FIG. 2. Separation of RRV capsids by velocity sedimentation. Pu-
rified capsids were separated by velocity sedimentation on a 20 to 50%
sucrose gradient (see reference 38). The three light-scattering bands in
the gradient are labeled A, B, and C capsids on the basis of a similar
banding pattern previously observed for KSHV.
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and the most prominent proteins migrated with apparent mo-
lecular masses of 134, 41, 34, and 16 kDa (Fig. 4, bands 1, 2, 4,
and 5, respectively). Additionally, the fraction that appeared in
TEM as an essentially pure population of type B capsids (Fig.
3C) contained a fifth protein migrating with an apparent mo-
lecular mass of 37 kDa (Fig. 4, band 3). This protein, unique to
B capsids, was therefore a good candidate for the RRV scaf-
folding homolog (SCAF). Of note, the fractions containing the
slowest- and fastest-sedimenting capsids (Fig. 2), respectively,
had identical protein profiles (Fig. 4, lanes 3 and 9). This last
result is consistent with our initial prediction that these two
bands were composed of type A and C capsids, respectively
(see above).
To confirm the identity of the five capsid-associated proteins
(Fig. 4), we analyzed each by tandem mass spectrometry and
then subjected the resultant tryptic peptides to the Sequest
search algorithm (National Center for Biotechnology Informa-
tion). Peptides that were not matched by this algorithm were
interpreted individually and searched against the expressed
sequence tag databases, also with the Sequest algorithm (38).
Figure 5 displays graphically the results of these analyses. Band
1 gave rise to 53 partially overlapping peptides spanning 738
amino acids and the unambiguous assignment of this 150-kDa
protein as RRV MCP, encoded by open reading frame 25
(ORF25). Similarly, analyses of the 39-kDa (Fig. 4, band 2)
and 30-kDa (Fig. 4, band 4) proteins generated seven peptides
spanning 78 amino acids and 12 peptides spanning 146 amino
acids, respectively. These results identified bands 2 and 4 as the
components of the triplex TRI-1 and TRI-2, encoded by
ORF62 and ORF26, respectively. Tryptic digestion of the 17-
kDa protein (Fig. 4, band 5) gave rise to five peptides spanning
55 amino acids, and sequence comparisons identified it as
RRV SCIP, which is encoded by ORF65. Likewise, the 35-kDa
protein (Fig. 4, band 3), present only in the B capsid fraction,
generated six peptides spanning 70 amino acids with a se-
quence identifying it as RRV SCAF, encoded by the predicted
ORF17.5 (11; M. Cruise, C. M. O’Connor, and D. H. Kedes,
unpublished observations). All five RRV capsid proteins show
sequence similarity to their KSHV homologs (Table 1). MCP
shows the greatest sequence conservation (84% similarity) be-
tween the two viruses, and SCAF shows the least (49% simi-
larity). The remaining capsid-associated proteins show signifi-
cant homology between the two viruses, with similarities
ranging between 56 and 81%.
Distinguishing between A and C capsids. Although TEM
demonstrated morphologically distinct capsid species that mi-
grated at different rates through sucrose gradients, corrobora-
tive biochemical identification of the three species requires
analyses of not only their protein but also their viral DNA
content. In contrast to B capsids that uniquely contain SCAF,
aiding in their identification (Fig. 4, lane 5), A and C capsids
demonstrate effectively identical protein profiles on SDS-
PAGE (Fig. 4, lanes 3 and 9). To distinguish between the latter
two species, we analyzed sequential fractions from the capsid
gradients for relative amounts of encapsidated (DNase-resis-
tant) RRV DNA with a fluorescently labeled DNA probe
complementary to RRV ORF65 by Southern dot blot analyses.
Results of this analyses are shown in Fig. 6A. The majority of
FIG. 3. Thin-section TEM of RRV capsids. (A) Mixture of three morphologically distinct capsids prior to separation. A capsids (thick arrow)
are empty icosahedral structures, B capsids (arrowhead) contain an inner ring-like structure likely composed of SCAF (see text), and C capsids
(thin arrow) contain a dense core consistent with encapsidated viral DNA. Velocity sedimentation separated the mixed capsid population into
distinct populations of A, B, and C capsids (B to D, respectively).
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the encapsidated DNA cosedimented with fractions containing
the rapidly sedimenting capsid population, labeled C in Fig. 2.
In contrast, gradient fractions containing the A and B capsids
showed little RRV DNA signal over the background. Coupled
with the protein analyses, these data confirm that the slowest-
sedimenting, empty capsids (Fig. 3B) are A capsids and the
fastest-sedimenting, dense-cored capsids (Fig. 3D) are C
capsids.
The C capsids are the most abundant of the three RRV
capsid species in our preparations (Fig. 2 and 6), representing
approximately 60% of the total capsids produced by our iso-
lation method 6 days after infection. This contrasts with our
earlier findings with KSHV based on similar capsid prepara-
tions from 12-O-tetradecanoylphorbol-13-acetate-induced pri-
mary effusion lymphoma cells. During KSHV lytic replication,
C capsids represent the least abundant (10 to 15%) of the three
capsid species (Fig. 6) (38). Since only those virions containing
intact viral genomes are potentially infectious, the number of C
capsid-containing particles correlates with the relative infectiv-
ity of particles released from lytically infected cells. Thus, this
finding may help explain the marked differences in the effi-
ciency of lytic replication between KSHV and RRV.
To address this issue directly with RRV, for which a plaque
assay on RhF exists (17), we measured the infectivity of gra-
dient-purified RRV virions and then compared this titer (in
PFU and PFU per milliliter) with the number of viral particles
or encapsidated genomes per milliliter. We found that a typical
500-ml preparation gave a titer of 6.6  106 PFU/ml in uncon-
centrated medium 6 days after infection. (This represents a
calculated titer after viral purification by size exclusion chro-
matography and velocity sedimentation through a sucrose gra-
dient.) We then determined the concentration of RRV parti-
cles in two ways. In the first, we estimated the amount of MCP
in each viral sample after its separation by SDS-PAGE and
subsequent staining with SYPRO Orange (Bio-Rad). The in-
tensity of staining with SYPRO Orange correlates with protein
mass and is affected little by other protein properties. We
compared the amount of MCP in each sample with known
concentrations of bovine serum albumin electrophoresed and
stained on the same gel by quantitative densitometry. Since
each particle contains 960 copies of MCP, we were then able to
approximate the number of virions in each sample. In the
second method, we determined the concentration of encapsi-
dated (DNase-resistant) RRV genomes within the purified
virions with a plasmid containing RRV ORF65 as our standard
and a dot blot Southern analysis with a probe to ORF65 as
described above. These two methods gave surprisingly close
estimates of 2.0  109 particles and 3.0  109 genomes per ml
FIG. 4. Protein composition of RRV capsids. (A) SDS-PAGE of capsid fractions from a 20 to 50% sucrose gradient (Fig. 2). Fractions 3, 5,
and 9 contain mainly A, B, and C capsids, respectively (see the corresponding micrographs, Fig. 3B to D). Fraction 4 is a mixture of both A and
B capsids. (B) Expanded view of fractions 3, 5, and 9. M, molecular mass standards (kilodaltons). The arrow and arrowheads to the right indicate
the five capsid-associated proteins migrating with the following apparent molecular masses: 1, 134 kDa; 2, 41 kDa; 3, 37 kDa; 4, 34 kDa; 5, 16 kDa.
The values on the left of each panel are molecular sizes in kilodaltons.
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of unconcentrated medium, respectively, indicating that nearly
all of the virions that we purified from medium 6 days after
infection contained RRV DNA. Nevertheless, these data also
suggest that the particle-to-infectivity ratio in the plaque assay
on RhF is 300:1 to 450:1.
Therefore, although it appears that nearly all of the released
virions contain genomes, the fraction that remains infectious
after our purification is small. This may reflect an inherent
inefficiency in the plaque assay, as well as potential damage to
the viral particles that we may introduce during the purification
process. Even so, the concentration of particles released into
the medium (according to either calculation) by RRV-infected
RhF exceeds that of induced KSHV-infected BCBL-1 cells by
approximately 30-fold (data not shown). Thus, RRV lytic rep-
lication, at least in culture, is both qualitatively and quantita-
tively distinct from that of KSHV, producing a higher propor-
tion of released particles that contain or are C capsids
(compare the relative amounts of A, B, and C capsids in Fig.
6A and B) as well as a greater total number of particles.
However, comparisons of the infectious titers of the two vi-
ruses remain as estimates, since, in contrast to RRV, there is
no currently available plaque assay for KSHV.
The differences in capsid and viral production between
KSHV and RRV in culture may also reflect, at least in part, the
FIG. 5. Mass spectrometric analysis of protein bands 1 to 5 in Fig. 4B. Peptides identified by tryptic digestion (shaded) are shown within the
sequence of the protein (black) they identified after screening of protein sequence databases. The protein bands are as follows: 1, MCP; 2, TRI-1;
3, SCAF; 4, TRI-2; 5, SCIP. Note that the translational start site and transcript of ORF17.5 (which encodes SCAF) is predicted from its homolog
in KSHV and other herpesviruses (see text).
TABLE 1. Comparison of protein components of RRV and KSHV








ORF25 MCP 153 153 71 84
ORF62 TRI-1 36 36 56 70
ORF26 TRI-2 34 34 65 81
ORF17.5 SCAF 31 29 38 49
ORF65 SCIP 17 19 40 56
a Percent identity and percent similarity were determined by using BLAST2
Sequences (BLAST2.2.1) with a BLOSUM62 matrix (National Center for Bio-
technology Information).
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distinctly different culture systems for growing the two viruses
rather than fundamental differences in their biology. With
KSHV, the capsid and viral preparations depend on reactiva-
tion of the viral genome from latently infected B-cell lines. In
contrast, the RRV system involves de novo infection of im-
mortalized fibroblasts and is marked by efficient entry into lytic
replication. Currently, no equivalent KSHV lytic culture sys-
tem exists for direct comparison. Even in recently developed
methods allowing de novo infection with KSHV, latency re-
mains the dominant mode of infection (4, 13, 32, 56). Signifi-
cant lytic reactivation arises only through exogenous initiation
of the lytic pathway either by chemical induction (e.g., addition
of 12-O-tetradecanoylphorbol-13-acetate or sodium butyrate
to the cells) (41, 45, 47, 60) or by introduction or activation of
an immediate-early gene (23, 32, 46, 53, 56). This notion that
the process of reactivation may limit the efficiency of KSHV
production in latently infected cells is supported by our pre-
liminary results indicating poor reactivation in rhesus macaque
B cells latently infected with RRV (B. Damania, A. Smith, and
D. H. Kedes, unpublished observations).
RRV as a model for KSHV. The present study indicates that
RRV is a potentially powerful model to help us understand the
intricacies of the structure and assembly of gammaherpesvi-
ruses, including the closely related human rhadinovirus,
KSHV. The inability to grow KSHV to high titers in cell cul-
ture has hampered studies addressing its structure, assembly,
and maturation (38, 57, 59). RRV, in contrast, demonstrates
robust lytic growth (2, 15–17, 31, 49). Nevertheless, the simi-
larities between RRV and KSHV are more remarkable than
their differences. In the present study, we have demonstrated
that (i) RRV also produces three capsid species (the A, B, and
C capsids) during lytic replication, (ii) the three RRV capsid
species (as shown by TEM) are similar in structure to those of
KSHV, (iii) RRV and KSHV possess a highly conserved pro-
tein composition, and (iv) both viruses assemble with similarly
slow kinetics.
The efficient de novo infection and lytic replication of RRV,
furthermore, lends itself more readily not only to refined struc-
tural analyses (58a) but also to a potentially more tractable
means of introducing genetic manipulation into the genes rel-
evant to assembly. These advantages can also lead to finer
compositional analysis, including the detection of low-abun-
dance capsid and virion-associated proteins (C. M. O’Connor
and D. H. Kedes, unpublished observations). Although work
with alpha- and betaherpesviruses continues to lead to further
insights into herpesvirus structure and assembly, extrapolation
of these findings to gammaherpesviruses runs the risk of miss-
ing subtle yet potentially important differences among the sub-
families. The RRV system allows direct study of a gammaher-
pesvirus that is evolutionarily related to the important human
pathogen KSHV. Exploration of both the similarities and dif-
ferences between these two primate rhadinoviruses should
yield further clues to their biology and pathogenesis.
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